Purpose: To evaluate the value of power Doppler sonography (PDS) in patients with a serum PSA level greater than 3.5 ng/ml and note the advantages of PDS in management of biopsy cores and staging in prostate cancer.
Material And Methods: A group of 579 patients with a serum PSA level greater than 3.5 ng/ml underwent sextant biopsies. PDS of the prostate was performed in all patients before biopsy indication. Patients underwent six initial sextant biopsies without Doppler. In 141 patients who retained an elevated serum PSA level, an additional series of six to eight ultrasound-guided biopsies with Doppler were indicated. A total of 299 cancers were diagnosed (126 palpable) after initial biopsies and 85 (13 palpable) after additional biopsies. One hundred seven patients with localized cancer (48 palpable) underwent a radical prostatectomy.
Results: An echographic or vascular anomaly was detected in 335 patients; after biopsies this anomaly corresponded to 260 cancers, 39 of which were not visible (false-negative Doppler results). The negative predictive value was 84% and there was no significant relation between PSA level and negative predictive value. After initial biopsies, if an abnormal Doppler signal was present the risk of having positive additional biopsies was 83%. Abnormal disoriented irregular vessels were present in 69% of patients with a Gleason score of 7 or higher versus 31% in patients with a Gleason score less than 7 (p<0.01). Twenty out of 39 patients with T1c cancer invisible with PDS and not palpable (13% of all cancers) underwent a radical prostatectomy. Eleven of 16 cancers with a Gleason score of 6 or less were found insignificant, but in two cases the lesion was advanced (p<0.01). Of cancers with a tumor vessel crossing the capsule, 71% presented an extraprostatic extension (Se: 37.5%, Spe: 93%, PPV: 71%, NPV: 78%) (p<0.01).
Conclusion: In prostatic cancer, PDS allows evaluation of aggressiveness features and can optimize the number of useful biopsy cores.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0221-0363(06)74128-2 | DOI Listing |
Clin Rheumatol
January 2025
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Cukurova University, Adana, Turkey.
Background: To evaluate the presence of type D personality and its association with metabolic syndrome (MetS), cardiovascular disease risk, and level of exercise in patients with psoriatic arthritis (PsA).
Material And Method: This cross-sectional study included patients with PsA (n = 84) and healthy controls (n = 74). Sociodemographic data, laboratory parameters, and disease-related parameters were recorded.
Int J Biol Macromol
January 2025
Department of Analytical Chemistry, Faculty of Chemistry, Razi University, Kermanshah, Iran.
This study introduces the development of a highly sensitive label-free electrochemical immunosensor specifically designed to detect prostate-specific antigen (PSA). A glassy carbon electrode (GCE) coated with Au nanoparticles/polyhedral hollow CoCu bimetallic sulfide (CuCoS) was employed as a sensing interface for the fixation of the monoclonal anti-PSA antibody. The nanoarchitectures enhanced the capacity for loading prostate-specific antibodies (Ab) and effectually boosted electrical conductivity leading to enhance the electrochemical signal and greater sensitivity for the detection of PSA.
View Article and Find Full Text PDFJ Vasc Interv Radiol
January 2025
Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands.
Purpose: To investigate the feasibility and safety of MRI-guided focal laser ablation (FLA) in localized, International Society of Urological Pathology (ISUP) grade 1-3, prostate cancer (PCa) using an integrated system.
Methods: Ten consecutive males (mean age: 66±7 years) with low-to-intermediate risk PCa were prospectively included (April 2022-May 2023) and treated with MRI-guided FLA using an integrated system for laser energy control and MR thermometry monitoring. Primary endpoints were technical success, procedure-related adverse events (AEs) following SIR (Society of Interventional Radiology) classification, and 12-months local tumor progression-free survival (LTPFS), defined as no evident residual/ recurrent disease on follow-up imaging or histopathology at the treatment site.
Clin Exp Metastasis
January 2025
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Oligorecurrent prostate cancer (PCa) can be treated with metastasis-directed therapy (MDT), which may be performed using radioguided surgery (RGS) as an experimental approach. These procedures have shown promising outcomes, largely due to the high lesion detection rate of positron emission tomography/computed tomography (PET/CT). We present a case series of patients who underwent RGS following robot-assisted radical prostatectomy (RARP).
View Article and Find Full Text PDFDigit Health
January 2025
Department of Neurology and Stroke Centre, Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital-Autonomous University of Madrid), Madrid, Spain.
Introduction: New technologies could play a role in post-stroke aphasia (PSA). Our aims were to develop a digital tool; to evaluate its acceptance and usability by patients and caregivers; and to demonstrate its effectiveness in improving language skills in patients with PSA, applying it from the acute phase.
Methods: The study consisted of two phases: development of a digital tool; and an interventional before-and-after study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!